Active — Not RecruitingNot Applicable

Efficacy of Flurbiprofen Spray for Postoperative Sore Throat Following Double-Lumen Endobronchial Intubation

Thailand58 participantsStarted 2025-09-10

Plain-language summary

The goal of this study is to evaluate whether topical flurbiprofen reduces the incidence and severity of postoperative sore throat (POST) and hoarseness in patients undergoing double-lumen tube (DLT) intubation for elective thoracic surgery. The main question is: Does topical flurbiprofen reduce POST and hoarseness compared with placebo in patients undergoing DLT intubation? Researchers will compare topical flurbiprofen spray with placebo spray. Participants will: * Receive a DLT sprayed with either topical flurbiprofen or placebo before intubation. * Be assessed for POST and hoarseness at 15 minutes, 2 hours, 12 hours, 24 hours, and 48 hours after surgery.

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient aged 20-80 years * Undergoing elective thoracic surgery * Requiring DLT intubation for lung separation * ASA physical status classification I-III * Able to communicate and understand the study Exclusion Criteria: * Contraindications to use of flurbiprofen, including allergies to flurbiprofen or NSAIDs, active peptic ulcer/ hemorrhage, history of gastrointestinal bleeding or perforation, severe colitis, severe heart failure, chronic kidney disease (CKD) stage IV or end-stage kidney disease (ESRD), or liver failure * Recent or recurrent upper respiratory tract infection * History of sore throat or hoarseness within 1 month prior to surgery * History of previous airway surgery * Chronic pain conditions * Pregnancy Withdrawal criteria * Fail DLT intubation * Inability to extubation at the end of surgery

What they're measuring

Incidence of POST

Timeframe: Within 48 hours postoperatively

Trial details

NCT IDNCT07163429

SponsorKittitorn Supphapipat, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31